by Clinical Neuropsychologist | Wednesday, October 23, 2024 | Dementia
Abstract BACKGROUND The magnitudes and patterns of alterations of the white–gray matter (WM–GM) functional connectome in preclinical Alzheimer’s disease (AD), and their associations with amyloid and cognition, remain unclear. METHODS We compared regional WM–GM...
by Clinical Neuropsychologist | Wednesday, October 23, 2024 | Dementia
Abstract INTRODUCTION People with dementia may benefit from psychological therapies for depression or anxiety, but evidence of their effectiveness in atypical dementia is limited. METHODS Using electronic health-care records of > 2 million people who attended...
by Clinical Neuropsychologist | Wednesday, October 23, 2024 | Dementia
Abstract BACKGROUND [18F] flortaucipir (FTP) binding to paired helical filament (PHF) tau in Alzheimer’s disease (AD) is well accepted. Binding to 3R and 4R tau in frontotemporal lobar degeneration (FTLD) is controversial. We aimed to investigate whether an FTP...
by Clinical Neuropsychologist | Wednesday, October 23, 2024 | Dementia
Abstract INTRODUCTION Assessing treatments for Alzheimer’s disease (AD) relies on reliable tools for measuring AD progression. In this analysis, we evaluate the sensitivity of clinical progression measures in AD within randomized controlled trials (RCTs) with...
by Clinical Neuropsychologist | Wednesday, October 23, 2024 | Dementia
Abstract BACKGROUND Metabolic dysregulation is a hallmark of neurodegenerative diseases, including Alzheimer’s disease (AD) and progressive supranuclear palsy (PSP). Although metabolic dysregulation is a common link between these two tauopathies, a comprehensive...
